Publications

1. Patarroyo-Rodriguez L, Vande Voort JL, Kung S, Brown SK, Cavalcanti S, Ritter MJ, Singh B. Non-Cardiac Chest Pain and Hypertensive Urgency During Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression Journal of Clinical Psychopharmacology. 2024.
   
2. Berger SR, Kung S, Lapid MI. Self-Rated ECT Outcomes in Patients With Depression: A Naturalistic Single-Site Study. J ECT. 2024 Nov 6 Epub 2024 Nov 06
   View PubMed
3. Bock J, Kung S, Ganesh R, Hurt RT, Lapid MI. Evaluating Repetitive Transcranial Magnetic Stimulation for Neuropsychiatric Symptoms in Long COVID: A Case Series. J ECT. 2024 Nov 1 Epub 2024 Nov 01
   View PubMed
4. Singh B, Kung S, Vande Voort JL. Intravenous (IV) ketamine versus intranasal esketamine for depression- Advantage IV ketamine? J Affect Disord 2024 Jul 1; 356:564-567 Epub 2024 Apr 22
   View PubMed
5. Singh B, Kung S, Poppe KA, Brown SL, Erickson C, Hale AM, Johnson BL, Jones KL, Pazdernik VK, Schak KM, Betcher HK, Moore KM, Ozerdem A, Veldic M, Frye MA, Bobo WV. Partial wake therapy and luminotherapy as an adjunct to usual care in hospitalized patients with depression - a pilot study. Psychiatry Res 2024 Jul; 337:115921 Epub 2024 Apr 25
   View PubMed
6. Aaronson ST, Goldwaser EL, Croarkin PE, Geske JR, LeMahieu A, Sklar JH, Kung S. A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression. J Clin Psychiatry. 2024 May 20; 85 (2)
   View PubMed
7. Singh B, Vande Voort JL, Pazdernik VK, Frye MA, Kung S. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine. J Affect Disord. 2024 Apr 15; 351:534-540 Epub 2024 Jan 30
   View PubMed
8. Kummerlowe MN, Kung S, Moore KM, Betcher HK. A First Trimester Exposure to Ketamine and Esketamine for Depression: A Case Report. J Clin Psychopharmacol. 2024 Apr 10 [Epub ahead of print]
   View PubMed
9. Cavalcanti S, Lopez OA, Kung S, Vande Voort JL, Somers K, Frye MA, Singh B. A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression. J Clin Psychopharmacol. 2024 Apr 10 [Epub ahead of print]
   View PubMed
10. Patarroyo-Rodriguez L, Pazdernik V, Vande Voort JL, Kung S, Singh B. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression. J Affect Disord. 2024 Mar 15; 349:272-276 Epub 2024 Jan 08
    View PubMed
11. Nunez NA, Coombes BJ, Beaupre LM, Ozerdem A, Resendez MG, Romo-Nava F, Bond DJ, Veldic M, Singh B, Moore KM, Betcher HK, Kung S, Prieto ML, Fuentes M, Ercis M, Miola A, Sanchez Ruiz JA, Jenkins G, Batzler A, Leung JG, Cuellar-Barboza A, Tye SJ, McElroy SL, Biernacka JM, Frye MA. Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorder. Transl Psychiatry. 2024 Feb 13; 14 (1):93
    View PubMed
12. Pagali SR, Kumar R, LeMahieu AM, Basso MR, Boeve BF, Croarkin PE, Geske JR, Hassett LC, Huston J 3rd, Kung S, Lundstrom BN, Petersen RC, St Louis EK, Welker KM, Worrell GA, Pascual-Leone A, Lapid MI. Efficacy and safety of transcranial magnetic stimulation on cognition in mild cognitive impairment, Alzheimer's disease, Alzheimer's disease-related dementias, and other cognitive disorders: a systematic review and meta-analysis. Int Psychogeriatr. 2024 Feb 8; 1-49 Epub 2024 Feb 08
    View PubMed
13. Lapid MI, Merrill J, Mueller M, Hermida AP, Nykamp L, Andrus J, Azizi H, Bolton P, Bonsu N, Braga R, Dillon CR, Ecklesdafer D, Evans D, Harper D, Heintz H, Hussain-Krauter S, Holzgen O, Humphrey D, Jiwani S, Johnson EK, Kang S, Kassien J, Kim J, Knapp RG, Kung S, Kremen N, Le K, Mahdasian J, Marzouk T, Masrud JD, Mattingly J, Miller D, Pagali SR, Patrick R, Riva Posse P, Pritchett C, Rahman A, Rath S, Roczniak C, Rummans TA, Sanghani S, Seiner S, Smart L, Tomaschek E, Tsygankova V, VanderSchuur-White L, Walton MP, Wilkins J, Williams A, Williams SM, Petrides G, Forester BP. Electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD): A modified study protocol. PLoS One. 2024; 19 (6):e0303894 Epub 2024 June 28
    View PubMed
14. Kosaski DL, Cole KC, Wright JA, El Melik RM, Kung S, Nicholson WT, Leung JG. Impact of sex on antidepressant discontinuation in groups of similar cytochrome P450 phenotypes. Ment Health Clin. 2023 Dec; 13 (6):303-310 Epub 2023 Dec 01
    View PubMed
15. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
    View PubMed
16. Lee NA, Kung S, Hu Y, Greenwaldt SE, Lapid MI, Croarkin PE. Depression and anxiety outcomes of adults undergoing intermittent theta burst stimulation (iTBS) treatment for major depressive disorder: A naturalistic study Journal of Mood and Anxiety Disorders. 2023; 3:100028.
    
17. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
    View PubMed
18. Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
    View PubMed
19. DeFoster RE, Morgan RJ 3rd, Leung JG, Schenzel H, Vijapura P, Kashiwagi DT, Fischer KM, Philbrick KL, Kung S. Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial. Subst Use Misuse. 2023; 58 (13):1643-1650 Epub 2023 July 19
    View PubMed
20. McManus KR, Lapid MI, Forester BP, Mueller M, Hermida AP, Nykamp L, Harper DG, Seiner SJ, Sanghani S, Patrick R, Gentry MT, Kung S, Leal JC, Johnson EK, Petrides G. Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials. J ECT. 2022 Sep 1; 38 (3):165-170 Epub 2022 Mar 01
    View PubMed
21. Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
    View PubMed
22. Collins AR, Cheung J, Croarkin PE, Kolla BP, Kung S. Effects of transcranial magnetic stimulation on sleep quality and mood in patients with major depressive disorder. J Clin Sleep Med. 2022 May 1; 18 (5):1297-1305
    View PubMed
23. Hu Y, Zhang H, Wang H, Wang C, Kung S, Li C. Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Res. 2022 May; 311:114468 Epub 2022 Feb 22
    View PubMed
24. Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
    View PubMed
25. Hu Y, Nassan M, Singh B, Croarkin PE, Kung S. Response rate underreports improvement in patients with major depressive disorder and comorbidities treated with repetitive transcranial magnetic stimulation (rTMS) Psychiatry Research Communications. 03/08/2022; 2(2).
    
26. Lapid MI, Atherton PJ, Kung S, Clark MM, Sloan JA, Whitford KJ, Hubbard JM, Gentry MT, Miller JJ, Rummans TA. A feasibility study of virtual group therapy to improve quality of life of cancer caregivers. J Psychosoc Oncol. 2022; 40 (6):854-867 Epub 2021 Nov 29
    View PubMed
27. Kung TL, Kung S, Kung JL, Michet J, Lapid MI. How Ya Doin'? with COVID-19 Journal of Emerging Investigators. 12/2/2021; 4:1-7.
    
28. Nunez NA, Sola C, Kung S, Singh B, Ozerdem A, Veldic M, Croarkin PE, Moore KM, Betcher HK, Vande JL, Geske JR, Biernacka JM, Rummans TA, Bahn RS, Frye MA. Deiodinase variation and liothyronine treatment interaction to accelerate ECT response in major depression: Pilot data and implications for thyroid pharmacogenomic testing in mood disorders Personalized Medicine in Psychiatry. 2021; 29-30.
    
29. Palmer BA, Pahwa M, Geske JR, Kung S, Nassan M, Schak KM, Alarcon RD, Frye MA, Singh B. Self-report screening instruments differentiate bipolar disorder and borderline personality disorder. Brain Behav. 2021 Jul; 11 (7):e02201 Epub 2021 May 30
    View PubMed
30. Hu Y, Kung S, Ozerdem A, Vande Voort JL, Singh B, McDonald WM, Riva-Posse P, Frye MA. Hypomania associated with high dose ketamine treatment. Bipolar Disord. 2021 Jun; 23 (4):426-428 Epub 2021 Feb 24
    View PubMed
31. Oroz R, Kung S, Croarkin P, Cheung J. Transcranial magnetic stimulation therapeutic applications on sleep and insomnia: a review. Sleep Science and Practice. 2021; 5.
    
32. Bates RE, Leung JG, Morgan RJ 3rd, Fischer KM, Philbrick KL, Kung S. Retrospective Analysis of Gabapentin for Alcohol Withdrawal in the Hospital Setting: The Mayo Clinic Experience. Mayo Clin Proc Innov Qual Outcomes. 2020 Oct; 4 (5):542-549 Epub 2020 Aug 19
    View PubMed
33. Nunez NA, Joseph B, Pahwa M, Seshadri A, Prokop LJ, Kung S, Schak KM, Vande Voort JL, Frye MA, Singh B. An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2020 Sep 14; 50 (4):137-163
    View PubMed
34. Cuellar-Barboza AB, McElroy SL, Veldic M, Singh B, Kung S, Romo-Nava F, Nunez NA, Cabello-Arreola A, Coombes BJ, Prieto M, Betcher HK, Moore KM, Winham SJ, Biernacka JM, Frye MA. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. Int J Bipolar Disord. 2020 Jul 4; 8 (1):23 Epub 2020 July 04
    View PubMed
35. Collins AR, Kung S, Ho JT, Wright JA, Dammen KC, Johnson EK, Lapid MI, Leung JG. Pharmacogenetic testing in psychiatric inpatients with polypharmacy is associated with decreased medication side effects but not via medication changes. J Psychiatr Res. 2020 Jul; 126:105-111 Epub 2020 May 10
    View PubMed
36. Gentry MT, Atherton PJ, Lapid M, Rosen PS, Kung S, Richardson J, Niazi SK, Bobo WV, Clark MM, Rummans TA. Effects of a multidisciplinary quality of life intervention on sleep quality in patients with advanced cancer receiving radiation therapy. Palliat Support Care. 2020 Jun; 18 (3):307-313
    View PubMed
37. Seshadri A, Clark MM, Kung S, Fuller-Tyszkiewicz M, Sood A, Dammen KC, Rico JA, Tye SJ, McGillivray J, Frye MA. Feasibility Study of Stress Management and Resiliency Training (SMART) in Patients With Major Depressive Disorder. Prim Care Companion CNS Disord. 2020 Apr 30; 22 (3)
    View PubMed
38. Sonmez AI, Kucuker MU, Kolla BP, Lewis CP, Kolla BP, Doruk Camsari D, Vande Voort JL, Schak KM, Kung S, Croarkin PE. Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8; 97:109763 Epub 2019 Oct 18
    View PubMed
39. Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S, Lewis CP, Croarkin PE. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res. 2019 Mar; 273:770-781 Epub 2018 Dec 07
    View PubMed
40. Ahmed AT, Biernacka JM, Jenkins G, Rush AJ, Shinozaki G, Veldic M, Kung S, Bobo WV, Hall-Flavin DK, Weinshilboum RM, Wang L, Frye MA. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. J Affect Disord. 2019 Mar 1; 246:62-68 Epub 2018 Dec 17
    View PubMed
41. Lee JH, Kung S, Rasmussen KG, Palmer BA. Effectiveness of Electroconvulsive Therapy in Patients With Major Depressive Disorder and Comorbid Borderline Personality Disorder. J ECT. 2019 Mar; 35 (1):44-47
    View PubMed
42. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol. 2019; 10:83 Epub 2019 Feb 19
    View PubMed
43. Shafi RMA, Kung S, Johnson EK, Lapid MI, Rasmussen KG. Decreasing Treatment Duration of Electroconvulsive Therapy (ECT) Using Daily Right Unilateral Ultrabrief Instead of Bitemporal ECT. J Psychiatr Pract. 2018 Nov; 24 (6):410-415
    View PubMed
44. Markota M, Coombes BJ, Larrabee BR, McElroy SL, Bond DJ, Veldic M, Colby CL, Chauhan M, Cuellar-Barboza AB, Fuentes M, Kung S, Prieto ML, Rummans TA, Bobo WV, Frye MA, Biernacka JM. Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Transl Psychiatry. 2018 Sep 10; 8 (1):188 Epub 2018 Sept 10
    View PubMed
45. Lapid MI, McNally Forsyth D, Hegard TL, Jazdzewski EA, Clobes JE, Ryan DA, Sola C, Sutor B, Kung S. Characteristics of Successful Transitions From Inpatient to Outpatient Electroconvulsive Therapy. J Psychiatr Pract. 2018 May; 24 (3):140-145
    View PubMed
46. Lapid MI, Kung S, Frye MA, Biernacka JM, Geske JR, Drake MT, Jankowski MD, Clarke BL. Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density. Transl Psychiatry. 2017 Aug 22; 7 (8):e1213
    View PubMed
47. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec; 206:300-304. Epub 2016 Sep 12.
    View PubMed
48. Lapid MI, Atherton PJ, Kung S, Sloan JA, Shahi V, Clark MM, Rummans TA. Cancer caregiver quality of life: need for targeted intervention. Psychooncology. 2016 Dec; 25 (12):1400-1407 Epub 2015 Sept 11
    View PubMed
49. Leung JG, Nelson S, Cunningham JL, Thompson VH, Bobo WV, Kung S, Dierkhising RA, Plevak MF, Lapid MI. A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. Clin Pharmacokinet. 2016 Aug; 55 (8):971-6
    View PubMed
50. Bommersbach TJ, Lapid MI, Leung JG, Cunningham JL, Rummans TA, Kung S. Management of Psychotropic Drug-Induced DRESS Syndrome: A Systematic Review. Mayo Clin Proc. 2016 Jun; 91(6):787-801. Epub 2016 Apr 25.
    View PubMed
51. Schutt PE, Kung S, Clark MM, Koball AM, Grothe KB. Comparing the Beck Depression Inventory-II (BDI-II) and Patient Health Questionnaire (PHQ-9) Depression Measures in an Outpatient Bariatric Clinic. Obes Surg. 2016 Jun; 26 (6):1274-8
    View PubMed
52. Rosen BH, Kung S, Lapid MI. Effect of Age on Psychiatric Rehospitalization Rates After Electroconvulsive Therapy for Patients With Depression. J ECT. 2016 Jun; 32: (2)93-8.
    View PubMed
53. Burton MC, Warren M, Cha SS, Stevens M, Blommer M, Kung S, Lapid MI. Identifying Patients in the Acute Psychiatric Hospital Who May Benefit From a Palliative Care Approach. Am J Hosp Palliat Care. 2016 Apr; 33: (3)228-32.
    View PubMed
54. Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, Palmer BA, Frye MA. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry. 2016 Mar 1; 173 (3):215-8
    View PubMed
55. Rasmussen KG, Johnson EK, Kung S, Farrow SL, Brown SK, Govrik MN, Citronowicz RI. An Open-Label, Pilot Study of Daily Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy. J ECT. 2016 Mar; 32: (1)33-7.
    View PubMed
56. Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA, Feeder SE, Tye SJ, Choi DS, Biernacka JM. Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry. 2015 Dec 8; 5 (12):e689 Epub 2015 Dec 08
    View PubMed
57. Kung S, Palmer BA, Lapid MI, Poppe KA, Alarcon RD, Frye MA. Screening for bipolar disorders: Clinical utilization of the Mood Disorders Questionnaire on an inpatient mood disorders unit. J Affect Disord. 2015 Dec 1; 188:97-100 Epub 2015 Sept 05
    View PubMed
58. Frye MA, McElroy SL, Fuentes M, Sutor B, Schak KM, Galardy CW, Palmer BA, Prieto ML, Kung S, Sola CL, Ryu E, Veldic M, Geske J, Cuellar-Barboza A, Seymour LR, Mori N, Crowe S, Rummans TA, Biernacka JM. Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. Int J Bipolar Disord. 2015 Dec; 3 (1):30 Epub 2015 June 24
    View PubMed
59. Lapid MI, Atherton PJ, Clark MM, Kung S, Sloan JA, Rummans TA. Cancer Caregiver: Perceived Benefits of Technology. Telemed J E Health. 2015 Nov; 21 (11):893-902 Epub 2015 June 15
    View PubMed
60. Prieto ML, McElroy SL, Hayes SN, Sutor B, Kung S, Bobo WV, Fuentes ME, Cuellar-Barboza AB, Crow S, Osby U, Chauhan M, Westman J, Geske JR, Colby CL, Ryu E, Biernacka JM, Frye MA. Association between history of psychosis and cardiovascular disease in bipolar disorder. Bipolar Disord. 2015 Aug; 17 (5):518-27 Epub 2015 June 09
    View PubMed
61. Yoshimatsu K, Rosen BH, Kung S, Palmer BA. Improvements in depression severity in hospitalized patients with and without borderline personality features. J Psychiatr Pract. 2015 May; 21 (3):208-13
    View PubMed
62. Hu C, Kung S, Rummans TA, Clark MM, Lapid MI. Reducing caregiver stress with internet-based interventions: a systematic review of open-label and randomized controlled trials. J Am Med Inform Assoc. 2015 Apr; 22 (e1):e194-209 Epub 2014 Aug 14
    View PubMed
63. McKean AJ, Lapid MI, Geske JR, Kung S. The importance of code status discussions in the psychiatric hospital: results of a single site survey of psychiatrists. Acad Psychiatry. 2015 Apr; 39(2):200-3. Epub 2014 Aug 21.
    View PubMed
64. Moyer AM, Walker DL, Avula R, Lapid MI, Kung S, Bryant SC, Edwards KK, Black JL, Karpyak VM, Shinozaki G, Jowsey-Gregoire SG, Ehlers SL, Romanowicz M, Litzow MR, Hogan WJ, Rundell JR, Hooten WM, Baudhuin LM. Relationship of genetic variation in the serotonin transporter gene (SLC6A4) and congenital and acquired cardiovascular diseases. Genet Test Mol Biomarkers. 2015 Mar; 19(3):115-23. Epub 2015 Feb 11.
    View PubMed
65. Frye MA, McElroy SL, Prieto ML, Harper KL, Walker DL, Kung S, Chauhan M, Crow S, Sutor B, Galardy CW, Veldic M, Palmer BA, Geske JR, Fuentes M, Cuellar-Barboza AB, Seymour LR, Mori N, Biernacka JM. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry. 2015 Feb; 76 (2):174-80
    View PubMed
66. Piderman KM, Kung S, Jenkins SM, Euerle TT, Yoder TJ, Kwete GM, Lapid MI. Respecting the spiritual side of advanced cancer care: a systematic review. Curr Oncol Rep. 2015 Feb; 17 (2):6
    View PubMed
67. Warren MB, Lapid MI, McKean AJ, Cha SS, Stevens MA, Brekke FM, Hegard TL, Kung S, Burton MC. Code status discussions in psychiatric and medical inpatients. J Clin Psychiatry. 2015 Jan; 76(1):49-53.
    View PubMed
68. Kumar Y, Kung S, Shinozaki G. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014 Dec; 28 (12):1143-8 Epub 2014 Aug 13
    View PubMed
69. Frye MA, Prieto ML, Bobo WV, Kung S, Veldic M, Alarcon RD, Moore KM, Choi DS, Biernacka JM, Tye SJ. Current landscape, unmet needs, and future directions for treatment of bipolar depression. J Affect Disord. 2014 Dec; 169 Suppl 1:S17-23
    View PubMed
70. Shahi V, Lapid MI, Kung S, Atherton PJ, Sloan JA, Clark MM, Rummans TA. Do age and quality of life of patients with cancer influence quality of life of the caregiver? J Geriatr Oncol. 2014 Jul; 5 (3):331-6 Epub 2014 Apr 14
    View PubMed
71. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, Oliver WC, Abenstein JP. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014 Feb 28; 215 (2):362-5 Epub 2013 Dec 21
    View PubMed
72. Shinozaki G, Kung S, Mrazek DA. Does 5HTTLPR long allele prevent hospitalization? Test of Hardy-Weinberg equilibrium. Psychiatr Genet. 2014 Feb; 24(1):34-6.
    View PubMed
73. Bhagia J, Kung S. The Need for More Autism Awareness in the Somali American Population. Glob Pediatr Health. 2014; 1:2333794X14550526 Epub 2014 Sept 23
    View PubMed
74. Chock MM, Lapid MI, Atherton PJ, Kung S, Sloan JA, Richardson JW, Clark MM, Rummans TA. Impact of a structured multidisciplinary intervention on quality of life of older adults with advanced cancer. Int Psychogeriatr. 2013 Dec; 25 (12):2077-86 Epub 2013 Sept 04
    View PubMed
75. Hoberg AA, Vickers KS, Ericksen J, Bauer G, Kung S, Stone R, Williams M, Moore MJ, Frye MA. Feasibility evaluation of an interpersonal and social rhythm therapy group delivery model. Arch Psychiatr Nurs. 2013 Dec; 27 (6):271-7 Epub 2013 Sept 12
    View PubMed
76. Shinozaki G, Kumar Y, Rosen BH, Rundell JR, Mrazek DA, Kung S. "Diminished" association between the serotonin transporter linked polymorphism (5HTTLPR) and body mass index in a large psychiatric sample. J Affect Disord. 2013 Oct; 151(1):397-400. Epub 2013 Jul 06.
    View PubMed
77. Shinozaki G, Romanowicz M, Mrazek DA, Kung S. HTR2A gene-child abuse interaction and association with a history of suicide attempt among Caucasian depressed psychiatric inpatients. J Affect Disord. 2013 Sep 25; 150: (3)1200-3.
    View PubMed
78. Lapid MI, Atherton PJ, Kung S, Cheville AL, McNiven M, Sloan JA, Clark MM, Rummans TA. Does gender influence outcomes from a multidisciplinary intervention for quality of life designed for patients with advanced cancer? Support Care Cancer. 2013 Sep; 21 (9):2485-90 Epub 2013 Apr 23
    View PubMed
79. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013 May; 27 (5):444-50 Epub 2013 Feb 20
    View PubMed
80. Shinozaki G, Romanowicz M, Passov V, Rundell J, Mrazek D, Kung S. State dependent gene-environment interaction: serotonin transporter gene-child abuse interaction associated with suicide attempt history among depressed psychiatric inpatients. J Affect Disord. 2013 May; 147: (1-3)373-8.
    View PubMed
81. Leedahl DD, Cunningham JL, Drake MT, Mundis CB, Kung S, Frye MA, Lapid MI. Hypovitaminosis D in psychiatric inpatients: clinical correlation with depressive symptoms, cognitive impairment, and prescribing practices. Psychosomatics. 2013 May-Jun; 54(3):257-62. Epub 2012 Dec 01.
    View PubMed
82. Kung S, Alarcon RD, Williams MD, Poppe KA, Jo Moore M, Frye MA. Comparing the Beck Depression Inventory-II (BDI-II) and Patient Health Questionnaire (PHQ-9) depression measures in an integrated mood disorders practice. J Affect Disord. 2013 Mar 5; 145 (3):341-3 Epub 2012 Sept 25
    View PubMed
83. Lapid MI, Drake MT, Geske JR, Mundis CB, Hegard TL, Kung S, Frye MA. Hypovitaminosis D in psychogeriatric inpatients. J Nutr Health Aging. 2013 Mar; 17 (3):231-4
    View PubMed
84. Kung S, Lapid MI, Swintak CC, Agarwal Z, Ryan SM, Lineberry TW. Survey of sensitive information written in patient notes by psychiatry trainees. Acad Psychiatry. 2013 Jan 01; 37(1):31-4.
    View PubMed
85. Kung S, Espinel Z, Lapid MI. Treatment of nightmares with prazosin: a systematic review. Mayo Clin Proc. 2012 Sep; 87 (9):890-900 Epub 2012 Aug 09
    View PubMed
86. Shinozaki G, Romanowicz M, Kung S, Rundell J, Mrazek D. Investigation of serotonin transporter gene (SLC6A4) by child abuse history interaction with body mass index and diabetes mellitus of White female depressed psychiatric inpatients. Psychiatr Genet. 2012 Jun; 22 (3):109-14
    View PubMed
87. Biernacka JM, McElroy SL, Crow S, Sharp A, Benitez J, Veldic M, Kung S, Cunningham JM, Post RM, Mrazek D, Frye MA. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord. 2012 Jan; 136 (1-2):e21-e29 Epub 2011 June 15
    View PubMed
88. Kung S, Ahuja Y, Iezzi R, Sampson SM. Posterior vitreous detachment and retinal tear after repetitive transcranial magnetic stimulation. Brain Stimul. 2011 Oct; 4(4):218-21. Epub 2011 Sep 06.
    View PubMed
89. Lapid MI, Cunningham JL, Hugo Z, Kung S. Acute dystonia associated with paliperidone overdose. Psychosomatics. 2011 May-Jun; 52(3):291-4. Epub 2011 Mar 02.
    View PubMed
90. Sampson SM, Kung S, McAlpine DE, Sandroni P. The use of slow-frequency prefrontal repetitive transcranial magnetic stimulation in refractory neuropathic pain. J ECT. 2011 Mar; 27(1):33-7.
    View PubMed
91. Shinozaki G, Romanowicz M, Kung S, Mrazek DA. A new interaction between SLC6A4 variation and child abuse is associated with resting heart rate. Depress Anxiety. 2011 Mar; 28(3):227-33. Epub 2010 Dec 13
    View PubMed
92. Forsyth DM, Poppe K, Nash V, Alarcon RD, Kung S. Measuring changes in negative and positive thinking in patients with depression. Perspect Psychiatr Care. 2010 Oct; 46 (4):257-65
    View PubMed
93. Rasmussen KG, Stevens SR, Kung S, Mohan A. Melancholic symptoms as assessed by the Hamilton Depression Rating Scale and outcomes with and without electroconvulsive therapy on an in-patient mood disorders unit. Acta Neuropsychiatr. 2010 Feb; 22(1):21-5.
    View PubMed
94. Kraft TL, Jobes DA, Lineberry TW, Conrad A, Kung S. Brief report: why suicide? Perceptions of suicidal inpatients and reflections of clinical researchers. Arch Suicide Res. 2010; 14(4):375-82.
    View PubMed
95. Kung S, Li X. The clinical use of pharmacogenomic testing in treatment-resistant depression. Primary Psychiatry. 2010; 17(5):46-51.
    
96. Conrad AK, Jacoby AM, Jobes DA, Lineberry TW, Shea CE, Arnold Ewing TD, Schmid PJ, Ellenbecker SM, Lee JL, Fritsche K, Grenell JA, Gehin JM, Kung S. A psychometric investigation of the Suicide Status Form II with a psychiatric inpatient sample. Suicide Life Threat Behav. 2009 Jun; 39(3):307-20.
    View PubMed
97. Petersen LR, Clark MM, Novotny P, Kung S, Sloan JA, Patten CA, Vickers KS, Rummans TA, Frost MH, Colligan RC. Relationship of optimism-pessimism and health-related quality of life in breast cancer survivors. J Psychosoc Oncol. 2008; 26(4):15-32.
    View PubMed
98. Kung S, Rummans TA, Colligan RC, Clark MM, Sloan JA, Novotny PJ, Huntington JL. Association of optimism-pessimism with quality of life in patients with head and neck and thyroid cancers. Mayo Clin Proc. 2006 Dec; 81(12):1545-52.
    View PubMed
99. Benjamin S, Robbins LI, Kung S. Online resources for assessment and evaluation. Acad Psychiatry. 2006 Nov-Dec; 30(6):498-504.
    View PubMed
100. Black DF, Kung S, Sola CL, Bostwick MJ, Swanson JW. Familial hemiplegic migraine, neuropsychiatric symptoms, and Erdheim-Chester disease. Headache. 2004 Oct; 44(9):911-5.
     View PubMed
101. Kung S, Lapid MI, Philbrick KL. An electronic filing cabinet for "classic" articles and other teaching materials: something old, something new. Acad Psychiatry. 2004 Summer; 28 (2):140-3
     View PubMed
102. Rasmussen KG Jr, Russell JC, Kung S, Rummans TA, Rae-Stuart E, O'Connor MK, O'Connor MK. Electroconvulsive therapy for patients with major depression and probable Lewy body dementia. J ECT. 2003 Jun; 19 (2):103-9
     View PubMed
103. Kung S, Mueller PS, Geda YE, Krahn LE. Delirium resulting from paraneoplastic limbic encephalitis caused by Hodgkin's disease. Psychosomatics. 2002 Nov-Dec; 43(6):498-501.
     View PubMed